Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Court challenge to NICE over Alzheimer's drugs

  • Comment
Campaigners and manufacturers today issued a High Court challenge against the decision by the National Institute of Clinical Excellence to bar drug treatments to patients with early and late-stage Alzheimer's Disease.

Campaigners and manufacturers today issued a High Court challenge against the decision by the National Institute of Clinical Excellence to bar drug treatments to patients with early and late-stage Alzheimer's Disease.

NICE guidance issued last November barred prescription of donepezil, rivastigmine and galantamine for early-stage Alzheimer's and memantine for late-stage disease.

Application for a judicial review was lodged this week by the Alzheimer's Society charity, following an application last week by Eisai and Pfizer, manufactuers of donepezil.

Neil Hunt, chief executive of the Alzheimer's Society, said. 'This is a fatally flawed decision and we are left with no choice but to challenge it in court.'

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.